The core module has received a Class II Medical Device License from the Taiwan Food and Drug Administration (TFDA), meeting clinical-grade accuracy standards and establishing a certified first-mover advantage.
Clinical validation has been completed across multiple medical settings, including hemodialysis units, long-term care facilities, emergency departments, and palliative care wards. These trials confirm strong technical maturity and high commercial viability across diverse healthcare environments.